



## Tandem Diabetes Care Announces Upcoming Conference Participation

October 30, 2024

SAN DIEGO--(BUSINESS WIRE)--Oct. 30, 2024-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will host meetings and present a company update at the following investor conferences:

- UBS Global Healthcare Conference on Thursday, November 14, 2024 at 11:45am Eastern Time (8:45am Pacific Time),
- Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024 at 11:30am Eastern Time (8:30am Pacific Time),
- Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 4:30pm GMT (11:30am ET, 8:30am PT), and
- Wolfe Research Healthcare Conference on Wednesday, November 20, 2024 at 8:40am Eastern Time (5:40am Pacific Time).

In addition, the Company will host meetings at the 2024 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 21, 2024.

The presentations will be webcast live, and an archive recording will be available for 30 days. The link to the live webcasts and archive will be accessible on Tandem Diabetes Care's Investor Center website located at <http://investor.tandemdiabetes.com> in the "Events & Presentations" section.

### About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company's pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit [tandemdiabetes.com](http://tandemdiabetes.com).

Tandem Diabetes Care, the Tandem logo, Control-IQ, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20241030276890/en/): <https://www.businesswire.com/news/home/20241030276890/en/>

### Media Contact:

858-366-6900

[media@tandemdiabetes.com](mailto:media@tandemdiabetes.com)

### Investor Contact:

858-366-6900

[IR@tandemdiabetes.com](mailto:IR@tandemdiabetes.com)

Source: Tandem Diabetes Care, Inc.